On March 27, 2016, a disclosure statement with respect to a plan of reorganization or liquidation was filed in the bankruptcy case of Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) and its affiliates.
The filing was assigned docket number 241 and is described on the court’s official docket as follows:
Amended Disclosure Statement // Disclosure Statement for the First Amended Plan of Reorganization of the Debtor (related document(s)) Filed by Nuo Therapeutics, Inc. (Bowden, William)
Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on January 26, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-10192. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Dentons US LLP is acting as lead bankruptcy counsel to Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) in the bankruptcy case.